Who
Stephen Basil Thomas
Director
Company insider
Files Form 4 as: Director, Climb Bio.
In numbers
- Trades disclosed
- 22
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $4.5M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 27 Jun 2024
- Last trade
- 15 Sep 2026
- Last filed
- 17 Sep 2026
Companies traded
Activity over time
1 Feb – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Sep 2026filed 17 Sep 2026 | CLYM Climb BioBiotechnology | SEC FORM 4 Sold | $1.4M100,000 at $13.67 | filing |
| 15 Sep 2026filed 17 Sep 2026 | CLYM Climb BioBiotechnology | SEC FORM 4 Sold | $1.4M100,000 at $13.67 | filing |
| 5 Jun 2026filed 8 Jun 2026 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 26 Feb 2026filed 27 Feb 2026 | CLYM Climb BioBiotechnology | SEC FORM 4 Sold | $114K16,313 at $7.01 | filing |
| 26 Feb 2026filed 27 Feb 2026 | CLYM Climb BioBiotechnology | SEC FORM 4 Sold | $114K16,313 at $7.01 | filing |
| 25 Feb 2026filed 27 Feb 2026 | CLYM Climb BioBiotechnology | SEC FORM 4 Sold | $236K33,687 at $7.00 | filing |
| 25 Feb 2026filed 27 Feb 2026 | CLYM Climb BioBiotechnology | SEC FORM 4 Sold | $236K33,687 at $7.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | CLYM Climb BioBiotechnology | SEC FORM 4 Sold | $58K10,000 at $5.81 | filing |
| 13 Feb 2026filed 17 Feb 2026 | CLYM Climb BioBiotechnology | SEC FORM 4 Sold | $58K10,000 at $5.81 | filing |
| 12 Feb 2026filed 17 Feb 2026 | CLYM Climb BioBiotechnology | SEC FORM 4 Sold | $471K90,000 at $5.23 | filing |
| 12 Feb 2026filed 17 Feb 2026 | CLYM Climb BioBiotechnology | SEC FORM 4 Sold | $471K90,000 at $5.23 | filing |
| 7 Aug 2025filed 11 Aug 2025 | CLYM Climb BioBiotechnology | SEC FORM 4 Code A | —100,375 at $0.00 | filing |
| 27 Jun 2025filed 1 Jul 2025 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —25,094 at $0.00 | filing |
| 27 Jun 2025filed 1 Jul 2025 | CLYM Climb BioBiotechnology | SEC FORM 4 Code M | —25,094 | filing |
| 4 Jun 2025filed 5 Jun 2025 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 27 Mar 2025filed 27 Mar 2025 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —25,093 at $0.00 | filing |
| 27 Mar 2025filed 27 Mar 2025 | CLYM Climb BioBiotechnology | SEC FORM 4 Code M | —25,093 | filing |
| 1 Jan 2025filed 3 Jan 2025 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —50,188 at $0.00 | filing |
| 1 Jan 2025filed 3 Jan 2025 | CLYM Climb BioBiotechnology | SEC FORM 4 Code M | —50,188 | filing |
News
No headline names them, or the companies they trade most, lately.